Piramal Pharma shares will be in focus after the US FDA's GMP inspection at its Turbhe facility from February 11-17, 2025, ...

The company's Q3FY25 consolidated profit plunged 63.6 percent to Rs 3.68 crore versus Rs 10.1 crore, while revenue rose 12.5 ...

Piramal Pharma slipped 1.14% to Rs 195.40 after the US FDA issued a Form-483 with 6 observations to the company's Turbhe facility post a GMP inspection.

The company stated that the observations primarily pertain to procedural improvements and are not related to data integrity.

Piramal Pharma's Turbhe facility in Navi Mumbai receives six observations from U.S. FDA inspection, company preparing detailed response.

Piramal Pharma has awarded its integrated media mandate to OMD India, part of Omnicom Media Group. Following a multi-round ...

Larsen & Toubro (L&T) has acquired the balance 26% stake in L&T Special Steels and Heavy Forgings (LTSSHF), an existing subsidiary of the company, from Nuclear Power Corporation of India (NPCIL) and ...

The Nifty Pharma index closed on a negative note on Thursday. Shares of Ipca Laboratories Ltd.(up 1.97 per cent), Gland ...

Piramal Pharma(numbers of share traded: 5.26 crore), NHPC(numbers of share traded: 5.08 crore), YES Bank(numbers of share ...

As part of the mandate, OMD will focus on improving Piramal Pharma’s market presence, brand awareness, consumer engagement, ...

The observations are mainly procedural and do not indicate any data integrity issues, Piramal Pharma added in a regulatory ...

OMD India will lead the strategic marketing and media efforts for the company's portfolio of OTC brands, including Lacto ...